EBF3
Basic information
Region (hg38): 10:129835233-129973053
Links
Phenotypes
GenCC
Source:
- hypotonia, ataxia, and delayed development syndrome (Strong), mode of inheritance: AD
- hypotonia, ataxia, and delayed development syndrome (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hypotonia, ataxia, and delayed development syndrome (HADDS) | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Genitourinary; Neurologic | 28017370; 28017372; 28017373 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (29 variants)
- Hypotonia, ataxia, and delayed development syndrome (18 variants)
- Inborn genetic diseases (6 variants)
- Intellectual disability;Global developmental delay;Expressive language delay;Hypotonia;Dyssynergia (1 variants)
- Isolated Pierre-Robin syndrome (1 variants)
- Hypotonia;Intellectual disability (severe) (1 variants)
- Neurodevelopmental disorder (1 variants)
- Autism spectrum disorder (1 variants)
- See cases (1 variants)
- Dyssynergia;Global developmental delay;Hypotonia;Expressive language delay;Intellectual disability (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the EBF3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 20 | 25 | ||||
missense | 25 | 63 | 103 | |||
nonsense | 14 | 16 | ||||
start loss | 0 | |||||
frameshift | 13 | 23 | ||||
inframe indel | 6 | |||||
splice donor/acceptor (+/-2bp) | 10 | |||||
splice region | 1 | 8 | 7 | 16 | ||
non coding | 7 | |||||
Total | 45 | 37 | 74 | 30 | 4 |
Variants in EBF3
This is a list of pathogenic ClinVar variants found in the EBF3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
10-129837933-A-G | not specified | Uncertain significance (May 13, 2022) | ||
10-129837935-T-A | Likely benign (Oct 09, 2018) | |||
10-129837958-T-C | Hypotonia, ataxia, and delayed development syndrome | Uncertain significance (Sep 19, 2020) | ||
10-129837960-G-A | Hypotonia, ataxia, and delayed development syndrome | Uncertain significance (Mar 29, 2024) | ||
10-129840237-A-C | Intellectual disability | Likely benign (Jan 01, 2019) | ||
10-129840255-A-C | Inborn genetic diseases | Uncertain significance (Feb 28, 2023) | ||
10-129840260-C-T | Inborn genetic diseases | Uncertain significance (Feb 14, 2024) | ||
10-129840261-G-A | Likely benign (Jul 26, 2018) | |||
10-129840267-G-A | EBF3-related disorder | Benign (Dec 31, 2019) | ||
10-129840294-T-TTGGGGCCTCG | Uncertain significance (Nov 06, 2023) | |||
10-129840307-AC-A | Pathogenic (Dec 06, 2017) | |||
10-129840309-G-A | Benign/Likely benign (Jul 01, 2024) | |||
10-129840312-C-T | Likely benign (Jun 01, 2024) | |||
10-129840320-C-T | Uncertain significance (Jan 04, 2024) | |||
10-129840339-G-A | EBF3-related disorder | Likely benign (Jul 12, 2019) | ||
10-129840398-GGAGGGTGACCGAA-G | Autism spectrum disorder | Uncertain significance (Aug 08, 2022) | ||
10-129840860-A-G | Likely benign (Jul 01, 2024) | |||
10-129840897-A-C | Uncertain significance (Mar 01, 2024) | |||
10-129840944-GCTGA-G | EBF3-related disorder | Uncertain significance (Oct 25, 2022) | ||
10-129840949-CTG-C | Hypotonia, ataxia, and delayed development syndrome | Likely pathogenic (Apr 09, 2020) | ||
10-129840963-GACTGCTGGGGAGT-G | Hypotonia, ataxia, and delayed development syndrome • Inborn genetic diseases | Pathogenic (Aug 29, 2024) | ||
10-129840969-T-C | Inborn genetic diseases | Uncertain significance (Jan 29, 2024) | ||
10-129840970-G-A | Hypotonia, ataxia, and delayed development syndrome | Pathogenic (Jan 05, 2021) | ||
10-129840997-G-A | Intellectual disability • Hypotonia, ataxia, and delayed development syndrome | Conflicting classifications of pathogenicity (Apr 04, 2022) | ||
10-129841014-G-A | Uncertain significance (Apr 30, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
EBF3 | protein_coding | protein_coding | ENST00000368648 | 16 | 128559 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 0.0000667 | 125543 | 0 | 1 | 125544 | 0.00000398 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.61 | 163 | 354 | 0.460 | 0.0000210 | 3612 |
Missense in Polyphen | 38 | 96.714 | 0.39291 | 950 | ||
Synonymous | 0.500 | 146 | 154 | 0.949 | 0.0000111 | 1061 |
Loss of Function | 5.05 | 1 | 31.7 | 0.0316 | 0.00000166 | 342 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000881 | 0.00000881 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Transcriptional activator (PubMed:28017373, PubMed:28017372, PubMed:28017370). Recognizes variations of the palindromic sequence 5'-ATTCCCNNGGGAATT-3' (By similarity). {ECO:0000250|UniProtKB:Q07802, ECO:0000269|PubMed:28017370, ECO:0000269|PubMed:28017372, ECO:0000269|PubMed:28017373}.;
- Pathway
- Differentiation of white and brown adipocyte
(Consensus)
Recessive Scores
- pRec
- 0.108
Intolerance Scores
- loftool
- 0.0389
- rvis_EVS
- -0.65
- rvis_percentile_EVS
- 16.44
Haploinsufficiency Scores
- pHI
- 0.136
- hipred
- Y
- hipred_score
- 0.773
- ghis
- 0.558
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.996
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ebf3
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- multicellular organism development;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II
- Cellular component
- nucleus
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;metal ion binding;protein dimerization activity